

Docket No.: 1372001-2006.1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Richard Franklin

Application No.: 10/762,566

Confirmation No.: 3220

Filed: January 23, 2004

Art Unit: 1614

For: FORMULATION AND METHODS FOR THE
TREATMENT OF THROMBOCYTHEMIA

Examiner: A.R. Hughes

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98. The items listed on the enclosed Form PTO/SB/08A (Formerly PTO-1449) may be deemed to be pertinent to the above-identified application and is made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☒ Enclosed is Form PTO/SB/08A.
2. ☒ Certain items listed on the enclosed PTO/SB/08A are not presented in the English language.
- ☐ For each of the following items, an English-language translation of that item or a portion thereof or a concise explanation of the relevance of that item is attached:
- ☐ For each of the following items, a concise explanation of that item is incorporated in page of the specification of the above-identified applications:
- ☒ For each of the following items, a corresponding U.S. or other English-language patent is enclosed. Please consider the U.S. or other English-language patents in accordance with the procedure set forth in MPEP § 609:
- Japanese Publication No.: 1996-504198
(English Equivalent: Canadian Patent Publication No. 2,150,033)

3. ☐ Submission in Accordance with 37 CFR § 1.97(b).

This Information Disclosure Statement is being filed

- ☐ With the application;
- ☐ Within three months of the filing date of a national application;
- ☐ Within three months of the date of entry of the national stage in an international application;
- ☐ Before the mailing date of a first Office Action on the merits;
- ☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114,

and NO FEE is due for consideration of this Information Disclosure Statement.

4. ☐ Submission in Accordance with 37 CFR 1.97(c).

This Information Disclosure Statement is being filed before the first mailing date of any of:

- a. A Final action under § 1.113;
- b. A notice of allowance under § 1.311; or either
- c. An action that otherwise closes prosecution in the application; and

is accompanied by one of:

- ☐ A fee is due for consideration of this Information Disclosure Statement and the fee is paid below; or
- ☐ This Information Disclosure Statement is accompanied by one of the certifications pursuant to 37 CFR § 1.97(e), and NO FEE is due for consideration of this Information Disclosure Statement.

5. ☒ Submission in Accordance with 37 CFR 1.97(d).

This Information Disclosure Statement is being filed after the mailing date of either:

- ☒ A Final action under § 1.113; or
- ☐ A notice of allowance under § 1.311,

whichever comes first, but before payment of the issue fee, and is accompanied by all of:

- a. One of the certifications pursuant to 37 CFR § 1.97(e), which is set forth below; and
- b. The petition fee under 37 CFR § 1.17(p), which is paid below.

6. ☒ Certification Pursuant to 37 CFR 1.97(e).

☒ The undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application not more than three months prior to the filing of this Information Disclosure Statement; or

☐ The undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(e) more than three months prior to the filing of this Information Disclosure Statement.


7. Fee Payment Being Made.

- ☒ Enclosed
 - ☐ \$180.00 fee for submission under 37 CFR § 1.97(c).
 - ☒ \$180.00 fee for submission under 37 CFR § 1.97(d).
- ☐ A check in the amount of \$[Amount] to cover the fee payment is enclosed.
- ☒ Payment by Credit Card.

- ☐ Charge the fee to Deposit Account No. 50-0320. A duplicate copy of this communication is attached.
- ☒ The Director is hereby authorized to charge payment of any additional fees associated with this Information Disclosure Statement or credit any overpayment to Deposit Account No. 50-0320.

July 29, 2010

Respectfully submitted,



Shelly M. Fujikawa
Reg. No. 56,190
FROMMER LAWRENCE & HAUG LLP
745 Fifth Avenue
New York, NY 10151
(P) 206-336-5673
Attorney for Applicant